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Objectives
Mortality in young people with perinatally acquired HIV infection (PHIV) following transfer to
adult care has not been characterized in the UK. We conducted a multicentre audit to establish
the number of deaths and associated factors.
Methods
Fourteen adult clinics caring for infected young people reported deaths to 30 September 2011 on
a proforma. Deaths were matched to the Collaborative HIV Paediatric Study, a clinical database
of HIV-infected children in the UK/Ireland, to describe clinical characteristics in paediatric care
of those who died post-transition.
Results
Eleven deaths were reported from 14 clinics which cared for 248 adults with PHIV. For the 11
deaths, the median age at transfer to adult care was 17 years (range 15–21 years), and at death
was 21 years (range 17–24 years). Causes of death were suicide (two patients), advanced HIV
disease (seven patients) and bronchiectasis (one patient), with one cause missing. At death, the
median CD4 count was 27 cells/μL (range 0–630 cells/μL); five patients were on antiretroviral
therapy (ART) but only two had a viral load < 50 HIV-1 RNA copies/mL. Nine had poor
adherence when in paediatric care, continuing into adult care despite multidisciplinary support.
Eight had ART resistance, although all had potentially suppressive regimens available. Nine had
mental health diagnoses.
Conclusions
Our findings highlight the complex medical and psychosocial issues faced by some adults with
PHIV, with nine of the 11 deaths in our study being associated with poor adherence and
advanced HIV disease. Novel adherence interventions and mental health support are required for
this vulnerable cohort.
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Introduction
Mortality in children with perinatally acquired HIV
infection (PHIV) has declined following the introduction
of antiretroviral therapy (ART), and this group is now
surviving into adulthood and transitioning from paediatric
to adult care [1,2]. However, adherence to medication
in adolescence is often poor, and complicated by issues
involving family, home and school circumstances. Some
young people with PHIV have lost one or both parents,
and may be a young carer for a relative with HIV infection.
HIV diagnoses are often surrounded by secrecy and stigma,
limiting support from family and friends [3,4]. Over half of
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UK children with HIV infection were born abroad [5] and
may struggle with immigration and cultural adjustment.
Higher rates of mental health problems and neurocognitive
impairment are reported in adolescents with PHIV, and these
factors may impact on adherence, although data are conflict-
ing [6–10]. Adolescents with PHIV who have transitioned to
adult care have a lower prevalence of virological suppression
compared with horizontally HIV-infected young people [11],
increasing the risk of disease progression, mortality and
onward transmission to partners and offspring.
While newly infected adults look forward to a near-
normal life expectancy [12], little is known about mortality
rates and predicted life expectancy for adults who acquired
HIV infection in early childhood. While deaths in paediatric
care are reported to the Collaborative HIV Paediatric Study
(CHIPS), a prospective cohort of > 95% of HIV-infected
children receiving care in the UK or Ireland, until recently
follow-up ceased on transfer to adult care. There was thus
no mechanism for routinely reporting deaths in adults
with PHIV in adult care, and thus it was unclear whether
the low mortality observed in paediatric care was being
maintained on transfer to adult care. We therefore con-
ducted a multicentre audit of a sample of adult HIV ser-
vices caring for young people with PHIV to establish the
number of deaths and factors associated with mortality,
including adherence to antiretroviral therapy (ART), mental
health issues and comorbidity.
Methods
A structured audit questionnaire was disseminated to
21 adult clinics during 2011 via the HIV Young Persons
Network (HYPNet), a multidisciplinary group of health pro-
fessionals and voluntary sector representatives working
with HIV-infected young people aged 13–24 years, largely
in the south-east of England. Clinics provided individual
patient data on each young person who had been in pae-
diatric care for at least 1 year and who had subsequently
transitioned to adult care and died by 30 September 2011.
Data collected included demographics, cause of death,
virological and immunological parameters at transition
and death, ART history, adherence, resistance, hospital
admissions, physical and mental health diagnoses, and
social history. A London voluntary sector organization also
reported deaths known to them and details were matched
to clinic returns. All reported deaths were subsequently
matched to CHIPS, to elucidate clinical characteristics at
the time of last paediatric report pre-transfer to adult care.
Questionnaire data were entered into an Excel database.
Mutations associated with resistance to ART were identi-
fied from the Stanford University HIV Database (Stanford
University, Stanford, California, USA). Potentially suppres-
sive ART regimens were defined as two or more fully active
drugs with two or more partially active agents available in
the year of death.
Crude mortality rates per 100 person-years and rate
ratios by age and type of HIV care (13–15 years old; 16–20
years old in paediatric care; 16–20 years old in adult care;
and ≥ 21 years old in adult care) for the UK and Ireland for
the most recent 5-year period (2006–2011) were generated
from CHIPS data using Poisson regression, in STATA (Stata
Corp, College Station, TX). Denominator person-years for
the whole CHIPS cohort were calculated from the date a
child was 13 years old or 1 January 2006, whichever was
later, to 30 September 2011. Young people in adult care
and no longer in CHIPS follow-up were assumed to be alive
until 30 September 2011 unless they were known to
have died. Adolescents with less than 1 year of follow-up
between presentation and the date of the last clinic visit or
death were excluded.
The audit was registered with Imperial College Healthcare
NHS Trust. The CHIPS cohort has ethical approval from the
London Multicentre Research Ethics Committee.
Results
Fourteen (67%) of the 21 adult clinics returned audit data
and together reported 11 deaths in young people with PHIV
following transfer to adult care. These deaths occurred
between September 2003 and March 2011. Six of those who
died were female, 10 had acquired HIV perinatally, and one
had parenteral HIV exposure during infancy. Nine were
Black African (eight born in Africa and one born in the
UK), one was White British and one was White other
European. The median age at transfer from paediatric to
adult services was 17 years (range 15–21 years), while the
median age at death was 21 years (range 17–24 years).
Cause of death
Table 1 presents clinical characteristics of the 11 patients
who died, at transition to adult services and also at death,
as well as cause of death, opportunistic infections and
comorbidities in adult care. Seven deaths were related
to advanced HIV disease (patients 2−6, 9 and 10), two to
suicide (patients 7 and 8) and one to complications of
bronchiectasis (patient 1), and for one the cause of death
was missing. Two deaths occurred in the hospital of the
reporting clinic, three in other hospitals, one in a hospice
and four in the community.
Antiretroviral therapy
The median CD4 count at transfer to adult services was
120 cells/μL (range 0–651 cells/μL), and at death was
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27 cells/μL (range 0–630 cells/μL). Of nine patients pre-
scribed ART at the time of transfer (the other two having
declined ART), only two had a viral load < 50 HIV-1 RNA
copies/mL at transfer. These two patients were also the only
two to have a viral load < 50 copies/mL at death, and
neither had any reported ART resistance. The remaining
nine patients had a history of poor adherence in paediatrics
(documented in clinical notes), which continued follow-
ing transition, with only two of the nine ever achieving a
viral load < 50 copies/mL in adult care. Reported reasons
for poor adherence included limited motivation (nine
patients), limited acceptance of diagnosis (three patients),
side effects (three patients) and limited adherence skills
(e.g. ability to plan) (two patients). All those with poor
adherence were offered multimodal support, including
support from clinical nurse specialists, community nurses
and health advisors, psychology and directly observed
therapy. Three patients had gastrostomies inserted to aid
adherence.
At the time of death, five patients were on ART, although
only two had a viral load < 50 copies/mL. Patients not on
ART at death had all declined previous offers of treatment.
Eight of the nine patients with a viral load > 50 copies/mL
at the time of death had ART resistance (two had single-
class, three dual-class, one triple-class and two four-class
resistance) (Table 1). However, all patients had potentially
suppressive treatment regimens available in the year of
their death.
Comorbidity
All but one of the patients had additional health problems,
many of which were HIV-related (Table 1), although
no patients had hepatitis coinfection. Three patients had
Pneumocystis carinii pneumonia in adult care. Mental
health problems were documented in nine of the 11 patients:
two had required in-patient mental health services for a
psychotic episode (with one going on to commit suicide),
while a further seven had a history of depression, and one an
eating disorder.
Social circumstances
At the time of death, three of the 11 young people were
living with one or both parents, four were living with
adoptive/foster parents, two were living alone and two
were alternating between family and friends. Ten had at
least one infected family member, and for three at least one
parent had died from an HIV-related illness. Six were in
education, one was employed and four were not in educa-
tion, employment or training. Two had been involved
with youth offending services. Six had previous involve-
ment with social services, most commonly in relation to
adoption/foster care.
Six were known to be sexually active (median age of
coitarche 16 years; range 15–20 years) with no reported
pregnancies. Three young people were known to smoke
and one was an ex-smoker. Six reported alcohol use, with
five not having this documented. Drug use was reported in
four cases, including cannabis alone (one patient), canna-
bis and ecstasy (one patient), cocaine (one patient) and
unspecified (one patient). Nine had attended peer support
services outside the hospital setting.
Mortality rates
Mortality rates for children and young people with PHIV
in CHIPS who were in paediatric care or who transferred to
adult care in the UK and Ireland are presented in Table 2.
A total of 996 patients aged 13 years and over between 1
January 2006 and 30 September 2011 were included in
the analysis. The crude mortality rate rose from 0.2 per 100
person-years [95% confidence interval (CI) 0.1–0.6] in
those aged 13–15 years in paediatric care to 0.9 (95% CI
0.3–2.3) for those aged ≥ 21 years in adult care, although
CIs were wide because of the low number of events. Simi-
larly, the mortality rate ratio was 4.9 (95% CI 1.1–22.0)
and 2.7 (95% CI 0.6–12.2) for those aged ≥ 21 years and
those aged 16–20 years in adult care, respectively, com-
pared with those aged 13–15 years in paediatric care
(P = 0.18).
Table 2 Estimated minimum* mortality rates by age and type of HIV care in perinatally HIV-infected young people, 2006–2011
Age group and type of care
No. of
deaths Person-years
Rate/100 person-years
(95% CI)
Rate ratio
(95% CI)
13–15 years, paediatric 3 1689 0.2 (0.1–0.6) 1.0
16–20 years, paediatric 2 786 0.3 (0.1–1.0) 1.4 (0.2–8.6)
16–20 years, adult† 4 825 0.5 (0.2–1.3) 2.7 (0.6–12.2)
≥ 21 years, adult† 4 458 0.9 (0.3–2.3) 4.9 (1.1–22.0)
CI, confidence interval.
*Mortality rates are considered ‘minimum estimates’ as not all adult clinics treating young people with perinatal HIV infection were included in the audit
and so additional deaths may have been missed.
†Three deaths were excluded from this analysis as they occurred prior to 2006.
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CHIPS data suggest that a total of 404 children had
transferred to 70 adult clinics in the UK and Ireland by 30
September 2011, of whom 248 transferred to the 14 clinics
providing data for this audit.
Discussion
This audit identified 11 young people with PHIV who had
died following transfer to one of 14 adult HIV clinics. Of
the 404 young people across the UK and Ireland who had
transferred to adult care in a similar time period, 248
transferred to one of these adult clinics and 156 transferred
elsewhere, for whom the mortality status is presently
unknown. Thus, the mortality rates presented here can be
considered minimum estimates of the size of the problem.
Although the mortality rate in the general population rises
in early adulthood, rates in our study remain much higher
than in the general population (2010 mortality rates for
male and female individuals in England and Wales were
0.03 and 0.02 per 100 population for 15–19-year-olds and
0.06 and 0.02 for 20–24-year-olds, respectively) [13].
Details of the 11 deaths reported in our audit highlight
the complex medical and psychosocial issues faced by
some young adults growing up with HIV infection. Seven
of the 11 deaths were considered to be directly related
to HIV progression, one was attributable to an exacerba-
tion of HIV-related bronchiectasis that had been present
from early childhood, and two were from suicide. The
prevalence of comorbidity was high and Pneumocystis
carinii pneumonia was the commonest opportunistic infec-
tion reported. Mental health problems were very common,
home circumstances often unstable, and drug and alcohol
use prevalent, highlighting the multidisciplinary needs of
this diverse group.
Comparable mortality data for horizontally infected
UK adults suggest that deaths directly related to HIV infec-
tion are decreasing and that nearly a third of deaths
are not HIV related [14]. For horizontally infected adults,
multidrug resistance, poor adherence to ART and not
taking ART contributed to only 14% of all the reported
deaths [15]. However, in our study nine of 11 deaths were
associated with poor adherence and advanced HIV disease,
with poor adherence patterns in paediatrics continuing in
adult care, highlighting the importance of combating bar-
riers to adherence soon after ART initiation. Other studies
have similarly shown that early patterns of adherence may
predict long-term adherence [16,17]. Our persistent low
levels of adherence despite multimodal support highlight
the need for novel interventions for this particular group.
A recent pilot intervention of motivational interviewing
and financial incentives linked to virological response in a
comparable cohort of poor adherers showed sustained
virological response in half of participants [18]. Such
interventions require assessment in much larger studies
which may be complex in nature as a consequence of
the study population having issues of attendance, adher-
ence, mental health and social instability. Although rates
of mother to child transmission of HIV in the UK have
been falling over the last decade, there continue to be
new diagnoses of PHIV, often in children originating from
Africa. As of March 2013 there were 1131 children with
HIV infection in paediatric care in the UK and Ireland
(A. Judd, Medical Research Council Clinical Trials Unit,
London, UK, personal communication). Novel interven-
tions need to be developed to address the health needs of
young people in this group.
The main limitation of this study is that reporting of
deaths in adult care is likely to be incomplete. Only 248 of
the 404 young people with PHIV who have transferred to
adult care to 30 September 2011 were seen at one of the 14
clinics included in our study, and it is therefore likely that
the number of deaths in this group in adult care is under-
reported. Notwithstanding, mortality rates post-transition
to adult care were still higher than comparable rates for
paediatric care.
Findings from this audit clearly highlight the need for
continued comprehensive surveillance of health outcomes
in young people with PHIV following transfer to adult care.
Several initiatives are now underway to tackle this issue.
Firstly, from 2012 onwards, young people transitioning
to adult care (as well as those who have already transi-
tioned) are being invited to join the UK Register of HIV
Seroconverters, a prospective cohort study of HIV-infected
individuals whose date of seroconversion can be estimated.
Characteristics of study participants are routinely matched
to the national register of deaths to estimate mortality.
Secondly, a growing proportion are being ‘flagged’ with the
national register of deaths to provide ongoing mortality
estimates that are not conditional on participating in a
study. Thirdly, those leaving CHIPS are now being linked
to the Survey of Prevalent HIV infections Diagnosed
(SOPHID) database as well as the UK Collaborative HIV
Cohort Study (CHIC), in order to maintain anonymous
surveillance in adult care. Fourthly, the Adolescents and
Adults Living with Perinatal HIV (AALPHI) cohort will give
further insight into long-term treatment and psychosocial
outcomes [19]. These new studies, which involve linking
and harmonizing paediatric and adult data sets, will enable
more accurate estimates of mortality rates in this group as
a whole, as well as clarifying the characteristics of young
HIV-positive patients transitioning into adult clinics.
Finally, within the EuroCoord network of excellence, a
working group has been formed to prioritize and ensure a
coordinated approach to this issue across Europe.
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